Darbesis40 mcg/0.4 ml

Darbesis is a long-acting, recombinant erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia in the following FDA-approved, evidence-supported settings:

• Anemia associated with chronic kidney disease (CKD): in patients on dialysis and in patients not on dialysis, to reduce the need for red blood cell transfusion.
• Anemia due to the effect of concomitant myelosuppressive chemotherapy: in patients with non-myeloid malignancies, where a minimum of two additional months of planned chemotherapy is expected.

Not Indicated For

• Patients with cancer receiving chemotherapy when the anticipated outcome of treatment is cure.
• Patients whose anemia can be adequately managed by transfusion alone.
• As a substitute for red blood cell transfusion in patients who require immediate correction of anemia.

Darbesis has not been shown to improve quality of life, fatigue, or patient well-being, and its use requires careful evaluation of the risks and benefits described under Precautions and Warnings.

Each pre-filled syringe or single-use vial contains Darbepoetin Alfa as the active ingredient, a hyperglycosylated analogue of recombinant human erythropoietin produced by recombinant DNA technology in mammalian (Chinese hamster ovary) cells.

Available strengths typically include 25, 40, 60, 100, 150, 200, 300, and 500 mcg per vial/syringe as a sterile, preservative-free or preservative-containing solution for injection, formulated with polysorbate 80 or albumin-based stabilizers depending on the formulation.

Darbesis is a synthetic, hyperglycosylated protein that stimulates erythropoiesis (red blood cell production) by the same mechanism as endogenous erythropoietin, but with a longer terminal half-life due to its increased sialic acid content. This allows for less frequent dosing compared to shorter-acting erythropoiesis-stimulating agents.

It is supplied as a clear, colorless, sterile solution for subcutaneous or intravenous injection and is used under medical supervision to manage anemia in chronic kidney disease and chemotherapy-induced anemia.

Darbesis belongs to the therapeutic class of Erythropoiesis-Stimulating Agents (ESAs), a subclass of hematologic/anti-anemic agents.

Mechanism of Action

Darbepoetin Alfa stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells, thereby increasing hemoglobin and hematocrit levels.

Pharmacokinetics

• Absorption: Following subcutaneous injection, peak serum concentrations occur at approximately 24-72 hours; bioavailability is roughly 37% (lower than intravenous).
• Distribution: Limited to the vascular space with a small volume of distribution.
• Elimination half-life: Approximately 21 hours (IV) to 46 hours (subcutaneous), substantially longer than epoetin alfa, allowing extended dosing intervals (weekly to once every 4 weeks).
• Metabolism/Excretion: Cleared primarily through receptor-mediated uptake and catabolism; renal excretion is minimal.

Darbesis is administered by subcutaneous or intravenous injection only, by or under the supervision of a qualified healthcare professional, or by a properly trained patient/caregiver for subcutaneous self-injection where appropriate.

• Do not shake the vial or syringe vigorously; vigorous shaking may denature the protein, reducing biologic activity.
• Inspect visually for particulate matter and discoloration before use; do not use if either is present.
• Do not dilute or mix with other drug solutions.
• Do not re-enter a single-use vial; discard unused portions.
• Allow the vial/syringe to reach room temperature before injection.

Darbesis is a large protein molecule and has minimal potential for classic pharmacokinetic (cytochrome P450-mediated) drug-drug interactions.

• Iron deficiency: Concurrent absolute or functional iron deficiency can reduce or blunt the response to Darbesis; supplemental iron therapy is often required to achieve and maintain adequate hemoglobin response and should be assessed before and during treatment.
• Other bone marrow suppressive therapies: Concomitant myelosuppressive chemotherapy may affect erythropoietic response and requires closer hemoglobin monitoring.

No clinically significant interactions with common antihypertensives, anticoagulants, or other routinely co-administered medications have been well established, though blood pressure should be monitored closely as described under Precautions and Warnings.

Adverse effects of Darbesis are generally related to increases in hemoglobin/hematocrit and blood pressure, or to injection-related reactions.

Common

• Hypertension (requires regular blood pressure monitoring; see Precautions)
• Headache
• Arthralgia and myalgia
• Injection site pain or reactions
• Edema
• Fatigue, dizziness
• Nausea, vomiting, diarrhea

Serious (Less Common but Clinically Important)

• Thromboembolic events, including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke (risk increases with higher hemoglobin targets; see Precautions and Warnings)
• Pure red cell aplasia (rare, antibody-mediated loss of response)
• Serious allergic/hypersensitivity reactions
• Seizures (reported, mostly in CKD patients)

Data on the use of Darbesis in human pregnancy are limited. Animal reproduction studies have shown adverse effects (increased post-implantation loss) at maternal exposures approximating recommended human doses. Darbesis should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision.

It is not known whether Darbesis is excreted in human milk. Because many drugs are excreted in human milk and the effects on a nursing infant are unknown, caution should be exercised, and a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Consult a physician before use during breastfeeding.

Boxed Warning: Increased Mortality, Cardiovascular, and Tumor Progression Risk

Erythropoiesis-stimulating agents, including Darbesis, increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence when administered to target a hemoglobin level greater than 11 g/dL.

• Chronic kidney disease: No trial has identified a hemoglobin target level, dose, or dosing strategy that does not increase these risks; use the lowest dose sufficient to reduce the need for red blood cell transfusions.
• Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression/recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers; use only for chemotherapy-induced anemia in the labeled setting, at the lowest dose needed to avoid transfusion, and discontinue following completion of a chemotherapy course.

Hypertension

Darbesis can cause or worsen hypertension. Blood pressure must be adequately controlled prior to initiation and monitored closely throughout treatment; uncontrolled hypertension is a contraindication (see Contraindications).

Seizures

Seizures have been reported in patients receiving Darbesis, particularly during the first several months of therapy in CKD patients; monitor for premonitory neurological symptoms.

Pure Red Cell Aplasia

If a patient develops loss of response, evaluate for neutralizing antibody-mediated pure red cell aplasia and discontinue Darbesis if PRCA is confirmed; do not switch to another ESA.

Lack of/Loss of Response

Evaluate for causes of inadequate response (e.g., iron, vitamin B12, or folate deficiency, infection, inflammation, bleeding, hemolysis, bone marrow fibrosis, underlying disease) before increasing the dose.

Overdosage of Darbesis can cause excessive erythropoietic response with hemoglobin/hematocrit levels above the desired range, which may be associated with serious cardiovascular events including hypertensive crisis. There is no specific antidote.

If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center. Management includes withholding the drug, close clinical and hemoglobin monitoring, and supportive care (including phlebotomy if clinically indicated) as directed by a physician.

Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard if the product has been frozen. Protect from light by keeping the vial/syringe in its original carton until the time of use. Do not shake; vigorous shaking may damage the protein and reduce its effectiveness. Keep out of reach of children.

Renal Impairment

Darbesis is specifically indicated for anemia of chronic kidney disease; dosing is individualized to hemoglobin response regardless of dialysis status, as described under Dosage and Administration.

Hepatic Impairment

No formal dose adjustment has been established; use with routine hemoglobin monitoring.

Elderly

No overall differences in safety or effectiveness have been observed between elderly and younger patients, but greater sensitivity in some older individuals cannot be ruled out; use the lowest effective dose with careful monitoring.

Pediatric Patients

See Pediatric Uses.

Duration of treatment with Darbesis depends on the underlying indication:

• Chronic kidney disease: Typically long-term/chronic therapy with periodic dose titration based on hemoglobin response, continued as long as clinically indicated under physician supervision.
• Chemotherapy-induced anemia: Continue for the duration of the chemotherapy course; discontinue following completion of a chemotherapy course, as continued use beyond this period has not been shown to provide additional benefit and increases risk.

Do not extend, shorten, or restart therapy without consulting the prescribing physician.

Erythropoiesis-Stimulating Agent (ESA); Recombinant Human Erythropoietin Analogue; Antianemic Agent.

Darbepoetin Alfa acts as an analogue of endogenous erythropoietin. It binds to the erythropoietin receptor on committed erythroid progenitor cells in the bone marrow, triggering intracellular signaling (via the JAK2/STAT5 pathway) that stimulates their proliferation and differentiation into mature erythrocytes, ultimately increasing circulating red blood cell mass and hemoglobin concentration. Its additional sialic acid residues (compared to endogenous erythropoietin and epoetin alfa) reduce receptor-mediated clearance, prolonging its serum half-life and permitting extended dosing intervals.

Darbesis is indicated for the treatment of anemia associated with chronic kidney disease in pediatric patients, with dosing individualized on a weight (mcg/kg) basis and adjusted according to hemoglobin response, similar to adult dosing principles.

Safety and effectiveness of Darbesis for chemotherapy-induced anemia in pediatric patients have not been established. Use in children requires close pediatric specialist supervision, with careful attention to blood pressure and hemoglobin monitoring given the same class-level cardiovascular and thrombotic risks that apply to adults.